The parallel sessions are grouped in 3 different themes:

1. Chemical Biology
2. Drug Discovery Projects
3. Technologies

In addition, the programme contains three open sessions: First Time Disclosures (I & II) and Recent Highlights in Medicinal Chemistry. For these sessions, the talks will be selected from the submitted abstracts.

For most of the below topics, a slot in the programme will be available for an oral communication selected out of the submitted abstracts.

Chemical Biology

• Addressing Cooperative Ligand Binding in Drug Discovery (EUCHEMS Session)
  Chair: Prof. Luc Brunsveld, Eindhoven University of Technology, NL
  
  
• Targeting Self-Associating Proteins & Biomolecular Condensates in Drug Discovery
  Chair: Prof. Raphaël Frederick, UCLouvain, BE
  
  
• Beyond PROTACS, Monovalent and Glues Degraders
  Chair: Dr Laura M. Luh, Bayer, DE
  
  
• Targeting Epigenetic Modifications in Cancer Therapy (ICBS Session)
  Chair: Prof. Zaneta Nikolovska-Coleska, University of Michigan, US
  
  
• Chemical Probes for Target Identification & Validation
  Chair: Dr Joanna Redmond, GlaxoSmithKline, UK

• In vivo Chemistry to Study Biological Mechanisms and to Develop Innovative Tools for Therapy and Diagnosis
  Chair: Dr Frédéric Taran, CEA/Saclay, FR
  
  
• Mining the Phosphosignaling Networks
  Chair: Dr Nadia Ahmad, Charles River, UK

Drug Discovery Projects

• Drug Discovery in Targeting Neurodegenerative Disorders (ACS Session)
  Chair: Dr Rong Huang, Purdue University, US
  
  
• Covalent Drugs
  Chair: Dr Samir Jegham, Sanofi, FR
  
  
• Rising Horizons of Small Molecule Immunotherapies and Beyond
  Chair: Prof. Antonio Macchiarulo, University of Perugia, IT
  
  
• New Treatments for Current and Future Pandemics
  Chair: Prof. Ana Martinez, CSIC, ES
  
  
• Time to Act Against Antimicrobial Resistance
  Chair: Prof. Maria-Jesus Pérez-Pérez, Instituto de Química Médica, ES
  
  
• Targeting RNA by Small Molecules
  Chair: Dr Hasane Ratni, F. Hoffmann-La Roche, CH
  
  
• Drugging the Undruggable: Targeting Transcription Factors (ACS Session)
  Chair: Dr Anthony Romero, Oric Pharmaceuticals, US
  
  
• Renaissance of Natural-Product Inspired Drug Discovery in the 21st Century
  Chair: Dr Boris Vauzeilles, Institut de Chimie des Substances Naturelles, FR

Technologies

• Bioanalytics for DD: New Developments and Applications of Affinity Selection – Mass Spectrometry
  Chair: Dr Didier Roche, Edelris, FR
  
  
• Innovative Synthetic Technologies for Drug Discovery
  Chair: Dr Cara Brocklehurst, Novartis, CH
  
  
• Hit Discovery with DNA-Encoded Libraries
  Chair: Dr Andreas Brunschweiger, TU Dortmund, DE
  
  
• AI in Drug Discovery (CPA Session)
  Chair: Dr Jiang Hualiang, Shanghai Institute of Materia Medica, CN
  
  
• Methods for Late-Stage Functionalization
  Chair: Prof. Tobias Ritter, MPI für Kohlenforschung, DE
  
  
• Gut Specific Targeting Strategies of Drug Candidates
  Chair: Dr Jan Willem Thuring, Janssen, BE
  
  
• Radiochemistry (AFMC Session)
  Chair: Prof. Sun Choi, Division of Medicinal Chemistry of Pharmaceutical Society, KR
  
  
• Next Generation Medicinal Chemistry – An EFMC² Session
  Chair: Dr Clara Christ, Bayer, DE

Open Sessions (selected from submitted abstracts)

• First Time Disclosures (I & II)
  Session Chairs to be announced
  
  
• Recent Highlights in Medicinal Chemistry
  Session Chair to be announced